An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Eton Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 9, 2024. The company focuses on developing treatments for rare diseases. A conference call and webcast will discuss the results at 4:30 p.m. ET on the same day. Investors can email questions or access the webcast on Eton's website.
Eton Pharmaceuticals, Inc. comunicherà i risultati finanziari del primo trimestre del 2024 il 9 maggio 2024. L'azienda è specializzata nello sviluppo di trattamenti per malattie rare. Si terrà una conferenza telefonica e un webcast per discutere i risultati alle 16:30 ET dello stesso giorno. Gli investitori possono inviare domande via email o accedere al webcast sul sito web di Eton.
Eton Pharmaceuticals, Inc. informará sobre sus resultados financieros del primer trimestre de 2024 el 9 de mayo de 2024. La compañía se centra en el desarrollo de tratamientos para enfermedades raras. Una conferencia telefónica y una transmisión web discutirán los resultados a las 4:30 p.m. ET del mismo día. Los inversores pueden enviar preguntas por correo electrónico o acceder a la transmisión web en el sitio web de Eton.
이튼 파마슈티컬즈, Inc.는 2024년 5월 9일에 2024년 첫 분기 재무 결과를 보고할 예정입니다. 이 회사는 희귀병 치료제 개발에 집중하고 있습니다. 같은 날 오후 4시 30분(동부 표준시)에 결과를 논의하기 위한 전화 회의와 웹캐스트가 진행될 예정입니다. 투자자는 이튼의 웹사이트에서 웹캐스트를 보거나 이메일로 질문을 보낼 수 있습니다.
Eton Pharmaceuticals, Inc. annoncera ses résultats financiers pour le premier trimestre de 2024 le 9 mai 2024. L'entreprise se concentre sur le développement de traitements pour les maladies rares. Une conférence téléphonique et une webdiffusion discuteront des résultats à 16h30 ET le même jour. Les investisseurs peuvent envoyer des questions par courriel ou accéder à la webdiffusion sur le site web d'Eton.
Eton Pharmaceuticals, Inc. wird am 9. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen für seltene Krankheiten. Eine Telefonkonferenz und ein Webcast werden die Ergebnisse um 16:30 Uhr ET am selben Tag besprechen. Investoren können Fragen per E-Mail senden oder den Webcast auf der Website von Eton ansehen.
Positive
None.
Negative
None.
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
*Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
